[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1330741110.png) @TomSilver39 Tom Silver

Tom Silver posts on X about $cytk, $vktx, amgn, onc the most. They currently have XXXXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.

### Engagements: XXX [#](/creator/twitter::1330741110/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1330741110/c:line/m:interactions.svg)

- X Week XXXXXX +381%
- X Month XXXXXX -XX%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX +48%

### Mentions: X [#](/creator/twitter::1330741110/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1330741110/c:line/m:posts_active.svg)

- X Months XX -XX%
- X Year XXX +54%

### Followers: XXXXX [#](/creator/twitter::1330741110/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1330741110/c:line/m:followers.svg)

- X Week XXXXX +0.22%
- X Month XXXXX +1.40%
- X Months XXXXX +8.90%
- X Year XXXXX +23%

### CreatorRank: XXXXXXXXX [#](/creator/twitter::1330741110/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1330741110/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::1330741110/influence)
---

**Social category influence**
[finance](/list/finance)  [stocks](/list/stocks)  [cryptocurrencies](/list/cryptocurrencies)  [countries](/list/countries) 

**Social topic influence**
[$cytk](/topic/$cytk), [$vktx](/topic/$vktx), [amgn](/topic/amgn), [onc](/topic/onc), [h2](/topic/h2), [stocks](/topic/stocks), [Sentiment](/topic/sentiment), [$vrca](/topic/$vrca), [$sndx](/topic/$sndx), [$regn](/topic/$regn)

**Top assets mentioned**
[Cytokinetics Inc. (CYTK)](/topic/$cytk) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) [Gilead Sciences, Inc. (GILD)](/topic/$gild) [Neurocrine Biosciences, Inc. (NBIX)](/topic/$nbix) [BridgeBio Pharma, Inc. Common Stock (BBIO)](/topic/$bbio) [United Community Banks, Inc. (UCB)](/topic/$ucb) [Acadia Pharmaceuticals Inc. (ACAD)](/topic/$acad) [One Cash (ONC)](/topic/$onc) [Amgen, Inc. (AMGN)](/topic/$amgn) [Exelixis Inc (EXEL)](/topic/$exel) [Madrigal Pharmaceuticals, Inc. Common Stock (MDGL)](/topic/$mdgl) [Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)](/topic/$rytm) [Kymera Therapeutics, Inc. Common Stock (KYMR)](/topic/$kymr) [Edgewise Therapeutics, Inc. Common Stock (EWTX)](/topic/$ewtx)
### Top Social Posts [#](/creator/twitter::1330741110/posts)
---
Top posts by engagements in the last XX hours

"JPM:" $VKTX 2Q25 Review: Qtr Highlighted by Progress in Both Ongoing SubQ/Oral VK2735 Trials.an attractive pure-play option to invest in the obesity market oppty with somewhat derisked mid-late stage assets. Remain OW.""  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1948210471498142004) 2025-07-24 02:35:47 UTC 9517 followers, 30.9K engagements


"Cowen:" TD Cowen's top ideas for Q3:25 performance include $NBIX $BBIO $UCB $RAPP $ACAD $URGN and $ONC. Companies we believe are most likely to post Q2 sales/earnings in excess of consensus include $ADAP $AMGN $ARGX $ARQT $ASND $BBIO $EXEL $GILD $IMCR $MDGL $ONC $NBIX $REGN $RYTM $SNDX $UCB and $VRCA.Sentiment toward biotech stocks improved through Q2 and enters H2 above the nadir reached in the spring. Though investors are still worried about the headwinds from Washington the worst fears have not borne out. Our analysis suggests generally solid Q2 financial performance. We are hopeful that"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1948416081217171561) 2025-07-24 16:12:48 UTC 9517 followers, 3030 engagements


"WF:" #Biotech Breaking the Billion: Predicting Blockbuster Trajectories For Drug Revenues: Spanning the nine therapeutic areas we analyzed early revenue milestonestypically $100MM-$300MM/Q by Q4-Q10strongly predict future blockbuster status. Hitting up to $250MM by Q7 was a consistent signal with an 86-100% probability of reaching $1B/year within 3-5 years of launch. For mega blockbusters our analysis indicates reaching $750MM/Q by Q13 is a reliable predictor of achieving $5B/year within X years of launch; categorized blockbuster drugs by therapeutic area: Oncology (n=21) Immunology (n=11)"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1944907336965087698) 2025-07-14 23:50:18 UTC 9513 followers, 6382 engagements


"$CYTK Catalysts: 1) August XX - Detailed Ph3 MAPLE-HCM results: Aficamten vs Metoprolol in oHCM; 2) 2H25: Potential approval of aficamten in China; 3) Dec XX 2025: Aficamten PDUFA in oHCM; 4) 1H26: Potential EMA approval of aficamten; 5) 1H26: Topline results for ACACIA-HCM"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1947357511989821743) 2025-07-21 18:06:25 UTC 9517 followers, 2145 engagements


"Trust:" 2H2025 - SMID Catalyst Preview: $KYMR $NRIX $CYTK $EWTX $ABSI $OABI: KYMR: KT-621 Ph1b AD data (4Q25E); looking for oral dupi-like activity in disease population; NRIX: Await Ph1 updates in expansion cohorts and confirmatory trial designs for bexo; Ph1 clinical updates for NX-2127 and NX-1607; CYTK: Ph3 MAPLE data (ESC25) could help formulary positioning; +ve afi label vs. mava could lead to further differentiation (PDUFA Dec 26); EWTX: A deepening of LVOT-G response for CIRRUS Part D data (2H25) could support share upside; ABSI: ABS-201 Ph1 POC data to validate superior"  
![@TomSilver39 Avatar](https://lunarcrush.com/gi/w:16/cr:twitter::1330741110.png) [@TomSilver39](/creator/x/TomSilver39) on [X](/post/tweet/1945742980314517679) 2025-07-17 07:10:51 UTC 9515 followers, 1918 engagements